Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 12:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 547 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Glycemic Control Clear all
Completed Phase 3 Interventional

Weight Loss Study for People With Type 2 Diabetes

NCT01601574
View directory record Official record
Conditions
Type 2 Diabetes, Overweight, Obesity
Interventions
Weight Watchers modified program, Standard Care group
Behavioral · Other
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 70 Years
Enrollment
563 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Birmingham, Alabama • La Jolla, California • Augusta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

Comparative Trial Between 3 Types of Insulin Infusion Protocols

NCT00582309
View directory record Official record
Conditions
Hyperglycemia
Interventions
Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
Procedure
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Chicago Heights, Illinois • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jun 22, 2015 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Reducing Distress And Improving Glycemic Control In Adults With Type 1 Diabetes

NCT02175732
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
'KnowIt', 'OnTrack'
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
19 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2019 · Synced Jul 22, 2026, 12:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Relationship Between Advanced Glycation Endproducts and Diabetes

NCT02662010
View directory record Official record
Conditions
Diabetic Retinopathy, Type 2 Diabetes Mellitus
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 80 Years
Enrollment
157 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 27, 2021 · Synced Jul 22, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional

Impact of Per Oral Pyloromyotomy (POP) on Glycemic Control in Diabetes

NCT04696159
View directory record Official record
Conditions
Diabetes Mellitus, Gastroparesis With Diabetes Mellitus, Gastroparesis
Interventions
Pyloromyotomy
Procedure
Lead sponsor
Matthew Allemang
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 22, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional

Use of CGM in Kidney Transplant Recipients

NCT04783441
View directory record Official record
Conditions
Kidney Transplant; Complications, Diabetes Mellitus, Type 2, Insulin Dependent Diabetes
Interventions
Dexcom G6, Dexcom G6 blinded sensor
Device
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 4 Interventional

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

NCT00060931
View directory record Official record
Conditions
Hypertension
Interventions
carvedilol, metoprolol
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 80 Years
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
119
States / cities
Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking Insulin Alone or With Other Oral Antidiabetic Agents

NCT03285594
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Insulin glargine (HOE901), Placebo, Oral Antidiabetes Drugs (OADs)
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
50
States / cities
Mesa, Arizona • Phoenix, Arizona • Huntington Park, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy

NCT02384941
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Placebo, Sotagliflozin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
63
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Escondido, California + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional

Timing of Meal Insulin Boluses for Optimal Postprandial Glycemic Control in Type 1 Diabetes

NCT01693302
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 30 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2012 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluate Effects of Sprinkled Format REDUCOSE in a Carbohydrate-rich, Mixed Meal on Post-prandial Glycemia

NCT04877366
View directory record Official record
Conditions
Dietary Supplement
Interventions
Dietary Supplement: Sprinkled Format REDUCOSE., Reference control, Active comparator
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
19 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 2 Interventional

Effect of PF-00734200 in Subjects With Type 2 Diabetes

NCT00618007
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
PF-00734200 30 mg QD, PF-00734200 20 mg QD, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
69
States / cities
Birmingham, Alabama • Chandler, Arizona • Litchfield Park, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2011 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

GLYCOSA Study:Effect of PAP Treatment on Glycemic Control in Patients With Type 2 Diabetes

NCT00509223
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Positive Airway Pressure therapy, Lifestyle counseling
Device · Behavioral
Lead sponsor
ResMed
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
11
States / cities
Mission Viejo, California • Temecula, California • Coral Gables, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2013 · Synced Jul 22, 2026, 12:41 AM EDT
Terminated Phase 2 Interventional Results available

The Efficacy of Glucagon Like Peptide (GLP) - 1(7-36) Amide for Glycemic Control in Critically Ill Patients

NCT00798590
View directory record Official record
Conditions
Critically Ill, Hypoglycemia
Interventions
Glucagon-Like Peptide-1, Saline
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Peanuts and Glycemic Control

NCT03654651
View directory record Official record
Conditions
Type2 Diabetes, Cardiovascular Diseases
Interventions
Peanut, High carbohydrate snack
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles

NCT01231984
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
Device
Lead sponsor
Becton, Dickinson and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Escondido, California • Atlanta, Georgia • Springfield, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

Naturlose (D-Tagatose) Efficacy Evaluation Trial

NCT00955747
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tagatose, Sugar Substitute Splenda
Drug
Lead sponsor
Robert Lodder
Industry
Eligibility
18 Years to 75 Years
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
21
States / cities
Hueytown, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 3 Interventional Results available

The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)

NCT01106690
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin, Sitagliptin, Metformin, Pioglitazone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
344 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Anniston, Alabama • Phoenix, Arizona • Tucson, Arizona + 38 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2013 · Synced Jul 22, 2026, 12:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Finding Diabetes Mellitus Among Veterans

NCT00007696
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Not listed
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
45 Years to 64 Years
Enrollment
1,276 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 1998
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 2, 2011 · Synced Jul 22, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional

CGM Academy for Youth With Type 1 Diabetes

NCT06408207
View directory record Official record
Conditions
Type1 Diabetes
Interventions
CGM Academy
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
8 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 3 Interventional

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

NCT00370565
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2007 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Phase 3 Interventional

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

NCT00288236
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Rimonabant (SR141716), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Jul 22, 2026, 12:41 AM EDT
Completed Not applicable Interventional Results available

Complete Health Improvement Program for Geisinger Health Plan Members With Type 2 Diabetes

NCT04924400
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
CHIP Program, Usual Care
Behavioral
Lead sponsor
Thomas Morland
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Danville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Jul 22, 2026, 12:41 AM EDT
Recruiting Not applicable Interventional

Study Comparing Acceptance and Commitment Therapy to Supportive Diabetes Counseling and a Waitlist Control for Eating Disorders in Type 1 Diabetes

NCT05540704
View directory record Official record
Conditions
Type 1 Diabetes, Eating Disorders, Disordered Eating Behaviors, Purging (Eating Disorders), Binge-Eating Disorder
Interventions
ACT, Supportive Diabetes Counseling
Behavioral
Lead sponsor
Duke University
Other
Eligibility
16 Years to 50 Years
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Durham, North Carolina • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 22, 2026, 12:41 AM EDT